周剂量泰索帝联合铂类方案治疗晚期非小细胞肺癌  

Clinical study of weekly docetaxel combination with cisplatin or carboplatin in treatment of advanced non-small cell lung cancer

作　　者：宋谦[1] 李露嘉[1] 侯晓伟[1] 夏放[1] 

机构地区：[1]解放军第401医院肿瘤科,山东青岛266071

出　　处：《中国现代医学杂志》2004年第17期136-137,139,共3页China Journal of Modern Medicine

摘　　要：目的评价泰索帝联合铂类对晚期非小细胞肺癌的临床疗效和毒性反应。方法晚期难治性非小细胞肺癌患者共30例,泰索帝25 mg/m2,静脉滴注1 h,第1,8,15天;顺铂25 mg/m2静脉滴注,第1,8,15天。28 d为1周期,至少治疗3周期。结果30例患者均可评价疗效,PR11例,NC16例,PD3例,有效率36.67%(11/30),毒性反应主要为恶心、呕吐和腹泻、肝功能损害、骨髓抑制、皮疹等。大部分患者为Ⅰ、Ⅱ度反应,患者耐受良好。结论泰索帝每周疗法联合铂类方案是一种对晚期非小细胞肺癌有效的治疗方案,毒性反应轻,临床使用安全。Objective: To evaluate the clinical response rate and toxic reaction of weekly docetaxel combination with cisplatin or carboplatin in the treatment of advanced non-small cell lung cancer. Methods: A total of 30 cases of advanced non-small cell lung cancer was enrolled in this study. Docetaxel 25 mg/m2, cisplatin 25 mg/m2 were given through intravenous dripping for d1, d8 and d15. The chemotherapy was repeated every 28 days. Each patient was given at least 3 cycles. Results: The response rates of all the patients were evaluated.There were 11 PR, 16 NC and 3 PD in the group. The overall response rate was 36.67 %(11/30). The major toxicity included nausea; vomiting and diarrhea, liver function impaired, myelosuppression, and skin eruption. The severity of these side was gradeⅠ～Ⅱ and well tolerated. Conclusion: Weekly docetaxel combination with cisplatin or carboplatin is effective in the treatment of advanced non-small cell lung cancer, with mild to moderate side effect and safety clinical practice.

关 键 词：泰索帝 非小细胞肺癌 药物疗法 

分 类 号：R734.2[医药卫生—肿瘤]